Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials

Taylor and Francis Group, Hematology, p. 160222083303005

Journal article published in 2016 by Richard T. Silver, Hans Carl Hasselbalch

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by